Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shortsellers Say Gingko BioWorks Is ‘Colossal Synthetic Biology Scam'

One Of 2021’s Biggest Biotech IPOs

Executive Summary

The company claims its synthetic biology technology will revolutionize manufacturing but its share have dipped after the fraud allegations.

You may also be interested in...



Zymergen Buy Will Enhance Ginkgo’s Services, Accelerate Growth

Troubled Zymergen will continue its ongoing restructuring efforts and Ginkgo, which has seen its own challenges since going public, will use Zymergen’s automation expertise to accelerate its growth.

Controversial Ginkgo Will Team With Persephone On Bacterial Delivery Of Microbial Therapies

Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.

KPMG Speaks On What 2022 Medtech Investment May Look Like

2021 was a busy year in the medtech investment space. How will 2022 compare?

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel